Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women | NEJM
Long-acting injectable cabotegravir (CAB-LA) given intramuscularly every 8 weeks was superior to daily oral TDF–FTC in preventing HIV infection among MSM and transgender women. Kudos for including transgender women in this study!